← Back to Search

1 for Amenorrhea

N/A
Waitlist Available
Led By Janet E Hall, M.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8-12 hours
Awards & highlights

Study Summary

The purpose of the study is to explore the way in which gonadotropins (pituitary hormones) are released into the body. The knowledge acquired in this study will be used for the diagnosis and treatment of reproductive endocrine disorders. We seek to investigate the baseline characteristics of the GnRH-induced gonadotropin pulsations of patients with the following diagnoses: Hypothalamic Amenorrhea (HA) Idiopathic hypogonadotropic hypogonadism (IHH) Polycystic ovarian disease (PCOD) Acquired hypogonadotropic hypogonadism (AHH) Premature Ovarian Failure (POF) **WE ARE CURRENTLY RECRUITING ONLY SUBJECTS WITH A DIAGNOSIS OF IHH.** This has been an extremely productive and pivotal protocol in the studies of female reproductive physiology and pathophysiology and continues to be critical for defining the neuroendocrine abnormalities in patients with reproductive disorders. In some cases, it is also helpful in the planning of subsequent therapy if so desired. It is important to note that minors have been included in this protocol, as many patients are extremely anxious to know more about their neuroendocrine disorder. With minors who would like to know if their disorder is correctable, this protocol may be followed up with administration of pulsatile gonadotropin-releasing hormone (GnRH).

Eligible Conditions
  • Amenorrhea
  • Hypogonadotropic Hypogonadism
  • Olfacto-Genital Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8-12 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-12 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of luteinizing hormone (LH) and FAS (free alpha subunit) pulses
Secondary outcome measures
Folic acid
Inter-pulse interval for LH and FAS pulses

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,936 Previous Clinical Trials
13,198,543 Total Patients Enrolled
6 Trials studying Amenorrhea
1,352 Patients Enrolled for Amenorrhea
National Institutes of Health (NIH)NIH
2,705 Previous Clinical Trials
7,507,041 Total Patients Enrolled
2 Trials studying Amenorrhea
108 Patients Enrolled for Amenorrhea
Janet E Hall, M.D.Principal InvestigatorMassachusetts General Hospital
10 Previous Clinical Trials
26,551 Total Patients Enrolled
3 Trials studying Amenorrhea
1,320 Patients Enrolled for Amenorrhea

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby May 2025